Articles Related to CD4
Development of SARS-Cov-2 Circulating Immune Complex Candidate, (CRCx) as A New Promising Vaccine Eliciting Broad Immune Response.
There is a need to develop a universal vaccine that can boost immunity to coronaviruses if some modifications in their structure occur. This is what we are dealing with nowadays: a virus that can mutate its structure, while immunity is standing still in facing the virus. We report on preclinical trials of CRCx 3 and CRCx 2 vaccine candidates in inducing an elevated level of positive neutralizing antibodies as well as a cellular immune response in an animal model to provide protection against SARS-CoV-2. Highly efficient protection against SARS-CoV-2 was obtained with three-dose immunization using 0.25 ml of CRCx vaccine with a 25-mm needle at 7-day intervals between successive injections. In addition, CRCx vaccine candidates exhibit efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of CRCx in a clinical trial.
AIDS: Signs to Management of the Disease
Acquired Immune Deficiency Syndrome (AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency
virus (HIV). They get it after being infected with the HIV virus. HIV (human immunodeficiency virus) is a retrovirus that primarily
infects components of the immune system.
HIV Sero-Discordant Couples in Southwest Nigeria: Prevalence and Associated Risk Factors
This is a cross-sectional multicenter study to determine the prevalence of HIV sero- discordancy and the associated factors. A total of 166 respondents had questionnaire-based interview. All the respondents were PLHIV and most(87%) have been in heterosexual relationship for at least one year.
Non-ARV Prescriptions and Medication Burden among Commercially Insured U.S. HIV Patients
Accelerated aging and higher co-morbidity prevalence have increased non-antiretroviral (ARV) medications for HIV patients. We examined, over a 12 month period, non-ARV medication burden among HIV-positive patients 18-49 and ≥50 years using a comprehensive U.S. healthcare claims database in an age-and-gender matched analysis (1:3 matching ratio of cases to controls). Primary outcomes of interest included the median and mean number of unique non-ARV drug substances during the one month period with the highest number of prescriptions filled for each individual, and the mean number of unique classes of medication.
Editorial Board Members Related to CD4
Subash Sad
Professor
Department of Biochemistry, Microbiology and Immunology
University of Ottawa
Canada
Department of Biochemistry, Microbiology and Immunology
University of Ottawa
Canada